ADC Therapeutics SA
$ 1.11
-2.63%
28 Jul - close price
- Market Cap 144,998,000 USD
- Current Price $ 1.11
- High / Low $ 1.15 / 1.10
- Stock P/E N/A
- Book Value -1.70
- EPS -0.97
- Next Earning Report 2026-08-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -7.06 %
- 52 Week High 4.98
- 52 Week Low 0.78
About
ADC Therapeutics SA, a biotechnology company focused on clinical stage oncology, develops Antibody Drug Conjugates (ADC) for patients suffering from hematologic malignancies and solid tumors. The company is headquartered in Epalinges, Switzerland.
Analyst Target Price
$5.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-04 | 2026-03-10 | 2025-11-10 | 2025-08-12 | 2025-05-14 | 2025-03-27 | 2024-11-07 | 2024-08-06 | 2024-05-06 | 2024-03-13 | 2023-11-07 | 2023-08-08 |
| Reported EPS | -0.21 | -0.04 | -0.3 | -0.5 | -0.36 | -0.29 | -0.42 | -0.38 | -0.56 | -1.03 | -0.58 | -0.58 |
| Estimated EPS | -0.2 | -0.2983 | -0.36 | -0.48 | -0.4143 | -0.41 | -0.39 | -0.46 | -0.56 | -0.5 | -0.63 | -0.57 |
| Surprise | -0.01 | 0.2583 | 0.06 | -0.02 | 0.0543 | 0.12 | -0.03 | 0.08 | 0 | -0.53 | 0.05 | -0.01 |
| Surprise Percentage | -5% | 86.5907% | 16.6667% | -4.1667% | 13.1064% | 29.2683% | -7.6923% | 17.3913% | 0% | -106% | 7.9365% | -1.7544% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-11 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ADCT
2026-07-27 20:11:32
BlackRock, Inc. has disclosed a 5.4% ownership stake in ADC Therapeutics SA, holding 6,857,815 shares of common stock. The filing indicates BlackRock has sole voting power over 6,765,332 shares and sole dispositive power over all 6,857,815 shares, with no shared powers reported. The Schedule 13G filing, signed by Managing Director Spencer Fleming, specifies that no single underlying client or investor holds more than five percent of ADC Therapeutics’ outstanding common shares.
2026-07-27 10:10:41
Orbimed Advisors LLC significantly reduced its stake in ADC Therapeutics SA (NYSE:ADCT) by 77.4% in Q1, selling 4.5 million shares but retaining 1.32 million shares valued at $4.94 million. Institutional investors collectively own 41.1% of the company, which reported a quarterly loss of $0.21 per share and has a "Hold" consensus rating with a $6.25 target price. The stock opened at $1.18, trading below its 50-day and 200-day moving averages.
2026-07-27 06:10:41
ADC Therapeutics SA is a Switzerland-based clinical-stage oncology drug discovery and development company. It focuses on developing antibody drug conjugates (ADCs) for the treatment of various cancers, with key drug candidates ADCT-301 and ADCT-402 in clinical trials. The company's main revenue source is its Product business, and as of Q1 2026, 205 institutions hold shares in the company, accounting for 69.09% of total shares.
2026-07-27 02:10:16
This article provides a detailed breakdown of the shareholder structure for ADC Therapeutics SA (ADCT), including major individual and institutional holdings. It lists the top shareholders by proportion, categorizes shareholders by type, and offers a historical view of institutional shareholding changes over several quarters. The data indicates significant institutional presence and shifts in holdings by various investment firms.
2026-07-26 02:40:23
ADC Therapeutics SA (ADCT) is a Switzerland-based clinical-stage oncology company specializing in antibody drug conjugates (ADCs) for cancer treatment. Despite healthy fundamentals and high growth potential, its stock price has been trending down in the medium term, though analysts rate it as a "Buy" with a target price of 1.83. The company boasts significant institutional ownership and has averaged 16.96% year-on-year revenue growth over the past three years.
2026-07-24 10:41:16
ADC Therapeutics SA (NYSE:ADCT) has received a consensus "Hold" rating from six research firms, with an average 1-year price target of $6.25. The company's stock recently traded at $1.23, down 1.1%, with a market cap of $155.9 million. Despite missing EPS expectations in its latest quarter, the company's revenue slightly beat estimates, and analysts anticipate -$0.88 EPS for the current year.
